Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date July 29, 2022 · Filed August 25, 2022
Section 16 reporting ended · disclosed 2022-08-25. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2020 Filed Apr 3, 2020 17:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-023278 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · derivative · entry 10 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 800,000 shares, of which 17,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 41 | $70.35 | $2,884.35 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 9 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,800 | $69.10 | $400,777.10 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $69.00 to $69.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 546 | $68.19 | $37,229.77 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,841 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $67.69 to $68.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $66.85 | $40,111.98 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,387 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.65 to $67.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $65.71 | $78,855.00 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,987 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.34 to $66.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,513 | $64.78 | $98,008.81 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,187 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.29 to $65.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,110 | $63.69 | $325,476.85 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,700 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.16 to $64.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,190 | $62.62 | $137,132.76 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,810 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.07 to $63.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-017551 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Class A Common Stock · 70,000 shares Expires 2029-05-10 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F5 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 70,000 shares Expires 2029-05-10 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F5 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Class A Common Stock · 125,000 shares Expires 2028-11-02 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F4 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 125,000 shares Expires 2028-11-02 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F4 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2027-10-18 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F3 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 25,000 shares Expires 2027-10-18 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F3 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 800,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Class A Common Stock · 800,000 shares Expires 2027-02-03 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One-fourth of the shares subject to the option vested on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 800,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0000899243-19-023630 · doc4.xml · derivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 800,000 shares Expires 2027-02-03 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One-fourth of the shares subject to the option vested on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.